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Abstract Transcription and expression of the urokinase (UPA) 
receptor (uPAR) are strongly stimulated by PMA. As for uPAR, 
the expression of cr2-MR is regulated by PMA in U937 cells. 
Ligand blotting experiments with the 39 kDa receptor-associated 
protein RAP, a ligand for (uZ-MR, indicated that (YZ-MR levels 
first increased and then decreased after PMA treatment. 
FACscan as well as immunoblotting analysis with cw2-MR-spe- 
cific antibodies showed an identical trend: cut-MR levels in- 
creased within the first day of treatment with PMA, decreased 
at later times, and totally disappeared by three days of treatment. 
The effect of PMA was not due to transcriptional down-regula- 
tion, as the cu2-MR mRNA level did not decrease at later times. 
Sensitivity of U937 cells to uPA-saporin, a toxin conjugate that 
reguires binding to uPAR for killing activity, was also markedly 
decreased. These results suggest that uPAR-mediated endocyto- 
sis depends on cu2-MR expression. 
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1. Introduction 
The urokinase receptor (uPAR) focusses proteolytic activity 
at the cell surface by specifically binding the plasminogen acti- 
vator urokinase (UPA) [I]. Receptor-bound uPA is not shielded 
from the specific inhibitor PAI- (plasminogen activator inhib- 
itor type-l), which binds uPAR-bound uPA and regulates cell 
surface proteolysis [2]. Unlike free uPA, uPA : PAI-I complexes 
are internalized and degraded [3-S], a process also requiring the 
d2-macroglobulin receptor (a2-MR [6,7]. &2-MR, also called 
low density lipoprotein (LDL) receptor-related protein, is a 
member of the LDL receptor family [S], and plays a role in 
binding and endocytosis of many ligands, like a2-macroglob- 
ulin : proteinase complexes, B-migrating very low den- 
sity lipoproteins enriched with apolipoprotein E, and lipopro- 
tein lipase (reviewed in [9]). cl2-MR is also involved in the 
internalization of bacterial and plant toxins, such as Pseudo- 
monas ueruginosu exotoxin A and the plant type I ribosome- 
inactivating protein saporin (SAP) [IO,1 I]. A conjugate be- 
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tween uPA and SAP was shown to be highly cytotoxic towards 
cells expressing uPAR, whereas cells devoid of uPAR and a2- 
MR were resistant [l2]. 
During PMA (tetradecanoyl-phorbol acetate)-induced dif- 
ferentiation of U937 cells, transcription of the uPAR gene is 
strongly stimulated [ 13,141. We have therefore studied the effect 
of PMA on the levels of CZ~-MR protein and mRNA. We find 
a time-dependent effect of PMA on r2-MR protein, with an 
initial increase and subsequent decrease. The a2-MR mRNA 
levels are increased at earlier times and remain detectable after 
prolonged stimulation. Down-regulation of a2-MR is accom- 
panied by inhibition of uPA-SAP cytotoxicity. 
2. Materials and methods 
2.1. Reugenrs 
Anti-uPAR monoclonal antibody R2 [15] was a generous gift of Drs. 
E. Ronne and G. Heyer-Hansen. The conjugate between active uPA 
and the toxin saporin, uPA_SAP, was prepared and purilied as de- 
scribed [12]. Purified, bacterially expressed 39 kDa receptor-associated 
protein RAP [6], a ligand for a2-MR, was a generous gift of Drs. A. 
Nykirer. S. Moestrup and J. Gliemann, as also were the anti-a2-MR 
polyclonal antibody that recognizes the a chain of a2-MR [16] and the 
purified a2-MR [17]. PMA was from Sigma. 
2.2. Cell culture 
U937 cells were grown in RPM I 1640 (Gibco Life Sciences) supple- 
mented with 10% fetal bovine serum. Differentiation was obtained by 
incubating cells (150~300,000/ml) with 150 nM PMA for different time 
intervals. 
2.3. Rudio-iodinution 
The a2-MR ligand 39 kDa RAP (receptor associated protein) was 
iodinated with Iodogen (Pierce Chemical Co.) as described before [IX] 
to a specific activity of 2.5 12.5 x 10’ cpm/pmol. 
2.4. Cylofluorimetric unulysis 
Surface expression of uPAR and a2-MR was analysed by cytofluori- 
metry. Cells were briefly acid-washed to dissociate ligands [19], incu- 
bated in 0.1 ml PBS with 50 pg/ml anti-uPAR antibody R2 or with a 
1 : 500 dilution of anti-a2-MR polyclonal antibody, for 30 min at 4°C. 
The cells were washed twice with PBS and resuspended in PBS contain- 
ing a 1 : 50 dilution of fluorescein-conjugated anti-mouse or anti-rabbit 
IgG antibody (Dakopatts, Copenhagen, Denmark). After 30 min at 
4°C. cells were washed twice and analysed by flow cytofluorimetry with 
a FACScan apparatus (Becton Dickinson, San Jose, CA). 
2.5. Ligund blotting unuly.ris 
Cells were lysed in 0.1 M Tris-Cl, pH 8.0, 0.15 M NaCl, 1% Triton 
X-100; lysates (15Opg proteins) were separated by 5 8% gradient SDS- 
PAGE in the absence of reducing agents and transferred to a nitrocel- 
lulose filter. The filter was preincubated in 140 mM NaCl. 10 mM 
HEPES, 2 mM CaCL, 1 mM MgCl,, pH 7.8, containing low fat (2%) 
dry milk and 0.05% Tween 20, and subsequently 16 hat 4°C in the same 
buffer containing I% bovine serum albumin and 100.000 cpm 
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‘*‘I-labeled RAP (50 PM). The filter was washed twice and autoradi- 
ographed at -80°C using an intensifying screen. As a positive control, 
purified a2-MR was run and blotted alongside. Competition (lo-100 
nM) was used to check specificity. 
2.6. Enrichment and immunoblotting of a,?-MR 
Cells were lysed in 0.1 M Tris-HCl, 1% Triton X- 100, 1 mM PMSF, 
pH 8.1, cleared at 14,000 rpm for 10 min at 4°C and supplemented 
with 3-[3-cholamidopropyldimethyl-ammonio]-l-propanesulfonic acid 
(CHAPS) in 10 mM HEPES buffer, pH 7.8 containing 140 mM NaCl, 
2 mM CaCl,, 1 mM MgCl,, to a final concentration of 0.2%. Cleared 
lysates were incubated overnight at 4°C with RAP-Sepharose (66 ~1 
resin/mg protein) (prepared by standard procedures, 0.3 mg RAP/ml 
CN-Br-Sepharose), the resin subsequently washed twice in the same 
buffer, the beads resuspended, boiled in Laemmli buffer without 
/3-mercaptoethanol, and centrifuged. Supernatants were electrophor- 
esed (5% acrylamide) in the absence of reducing agents. The gel was 
blotted onto a nitrocellulose membrane (Schleicher and Schuell, Dassel, 
Germany), which was blocked in TBS buffer, 3% bovine serum albumin 
(BSA), included in a 1: 1000 dilution of polyclonal rabbit anti-a2-MR 
(a chain) serum in TBS, 0.5% BSA for 2 h at room temperature, 
extensively washed and incubated with “‘1 labeled protein A (Amer- 
sham; 0.2~Cilml TBS, 0.5% BSA) for 40 min at room temperature. The 
filters were then washed and autoradiographed at -80°C. 
2.7. Cytotoxicity assays 
Cytotoxicity assays with U937 cells were based on [‘Hlleucine incor- 
poration and have been described before [12]. PMA-containing medium 
was removed before the cell killing assay and replaced by fresh, PMA- 
free medium. 
2.8. RT-PCR analysis of aZ-MR mRNA levels 
Total RNA was purified from PMA treated or untreated U937 cells 
as described [20]. RNA was reverse-transcribed according to a pub- 
lished procedure [21] except that oligo(dN), was used instead of 
oligo(dT),z_,, to prime the reaction. First strand cDNA corresponding 
to 50 ng total RNA was amplified in 50~1 reactions containing 2.5 mM 
MgCl,, 100 mM Tris-HCI, pH 8.3, 50 mM KCI, 0.2 mM each dNTP, 
1 U Taq polymerase and 1 PM of the primers a2-MR2d (5’-GGAT- 
GTCCAGGCTTAGCCCAT-3’) and a2-MR2u (S-ACAATGTGGA- 
GGGTGTGGCC-3’). The primers a2-MR2d and a2-MR2u amplify a 
321 bp fragment from human a2-MR cDNA. Amplification was per- 
formed by 40 cycles of denaturation at 94°C for 30 s, annealing at 63°C 
for 1 min, extension at 72°C for 1 min. Negative control reac- 
tions without reverse transcriptase and without RNA were run in 
parallel. 
3. Results 
3.1. Expression of a2-MR is first up-regulated and then down- 
regulated by PMA in U937 cells 
Surface exposure of UPAR and a2-MR was tested with 
specific antibodies and FACscan analysis. PMA treatment of 
U937 cells caused a large time-dependent increase of uPAR- 
specific fluorescence (Fig. 1) mostly at 20 h in agreement with 
previous observations [13]. PMA treatment caused an initial 
increase of cell surface a2-MR fluorescence at 20 h, but was 
then followed by a decrease. By 72 h, essentially no specific 
signal could be observed at the U937 cell surface. 
To confirm the decrease of a2-MR, we have used ligand blot 
analysis to the iodinated a2-MR ligand RAP [22,23]. To this 
goal, equal amounts of proteins extracted from U937 cells 
treated for various lengths of time with PMA were separated 
by 5-S% gradient SDS-PAGE in the absence of reducing 
agents, blotted on a nitrocellulose filter and probed with 
[‘*‘I]RAP. Purified a2-MR was used as positive control. 
[‘251]RAP recognized an about 600 kDa band in U937 cell 
extracts which co-migrated with authentic purified a2-MR, but 
nevertheless was barely visible (compare lanes 1 and 2; Fig. 2A). 
The amount of [‘*‘I]RAP-binding protein in cell extracts was 
increased at 20 h of PMA treatment, decreased after this time, 
and had completely disappeared at 72 h (lanes 335). Binding 
was specific and could be out-competed by unlabeled RAP (not 
shown). 
Immunoblotting analysis of the level of a2-MR during PMA- 
induced differentiation also gave similar results. To detect a2- 
MR, a prior enrichment from the cell lysates with a RAP- 
Sepharose resin was necessary (see section 2). In control U937 
cell lysates we observed a band co-migrating with purified a2- 
MR. Its intensity was increased at 20 h of PMA treatment but 
became hardly visible at 48 and 72 h (Fig. 3). 
3.2. PMA treatment reduces sensitivity to the cytotoxic 
UPA-SAP conjugate 
We have previously shown that the uPA-SAP conjugate was 
highly and specifically cytotoxic towards cells expressing uPAR 
and a2-MR, including U937 cells [12], indicating that both 
receptors are necessary for mediating uPA-SAP endocytosis. 
Increase of uPAR by PMA treatment at 72 h would be expected 
to increase the cytotoxic activity of uPA-SAP. On the other 
hand, loss of a2-MR would be expected to have the opposite 
effect. We have first tested the uPA-SAP binding to purified 
a2-MR using unlabeled uPA-SAP as a competitor of [‘251]RAP 
binding (Fig. 2B). The control behaved in the expected way, i.e. 
10 nM unlabeled RAP (200-fold excess with respect to 
[‘251]RAP totally competed for binding. At IO nM, the uPA- 
SAP conjugate had a weaker competing activity than RAP, but 
completely extinguished the signal at 100 nM. We have there- 
fore tested the effect of PMA treatment on the killing activity 
of uPA-SAP in U937 cells. As shown in Fig. 4A, a 72 h PMA 
treatment of U937 cells resulted in a several-order of magnitude 
decrease in sensitivity to uPA-SAP. We also studied the sensi- 
tivity to uPA_SAP of cells which had been exposed to PMA for 
different times. As shown in Fig. 4B, U937 cells acquired re- 
sistance to uPA-SAP in a time-dependent fashion which 
was similar to the effect of PMA on a2-MR (see Figs. 2A 
and 3). 
3.3. aZ-MR down-regulation is not due to decreased 
transcription 
To gain further insight in the mechanism underlying a2-MR 
down-regulation, we extracted total RNA from control and 
PMA-treated U937 cells and tested for the presence of a2-MR 
mRNA by RT-PCR. As a positive control, we used HepG2 
cells that express high levels of a2-MR [24]. In untreated cells, 
a2-MR was barely detectable (Fig. 5, lane 1); however, treat- 
ment with PMA resulted in a clear signal both at 6 and 24 h 
of treatment (lanes 2-3). At 72 h, the level of mRNA was not 
decreased with respect to the 24 h signal (lane 4). 
4. Discussion 
The a2-MR protein and mRNA undergo regulation in 
several instances: they are increased during differentiation of 
trophoblasts to syncytiotrophoblasts [25] and by colony stimu- 
lating factor-l in murine macrophages [26]. Moreover, tissue 
macrophages exhibit a higher expression of a2-MR with re- 
spect to blood monocytes [27-291. Therefore, we investigated 
the regulation of a2-MR in U937 cells during PMA-induced 
differentiation. Treatment of U937 cells in vitro with PMA 
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Fig. 1. Effect of PMA on surface expression of uPAR and a2-MR. Acid-washed U937 cells were incubated with 150 nM PMA for 0 (B and G), 20 (C 
and H). 48 (D and I), and 72 h (E and J). Half of the cells (B, C, D, and E) were challenged with the monoclonal anti-uPAR antibody R2, the other 
half (F, G, H. I, and J) with a2-MR-2 polyclonal antibody. Controls (A, F) refer to cells treated only with the fluorescein-conjugated anti-antibody. 
causes terminal differentiation towards a monocyte-macro- 
phage phenotype with the appearance of new functions like 
adherence to the plastic dish, phagocytosis and the expression 
of specific surface markers [30,31]. In U937 cells PMA increases 
transcription and translation of the uPAR gene [13,14] as well 
as its surface exposure (Fig. 1, and data not shown). 
PMA has a dual effect on a2-MR. increasing it at 20 h and 
decreasing it at later times (48 and 72 h). Surface expression 
(Fig. 1) and the total content of a2-MR protein (Fig. 2A and 
3) indeed correlate with this behaviour. 
Several observations indicate that PMA treatment affects the 
internalization of uPAR-bound ligands, and that this may be 
due to down-regulation of a2-MR. RAP binding to purified, 
immobilized a2-MR is displaced by uPA-SAP in a dose- 
A 
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Fig. 2. Effect of PMA treatment on U937 cells a2-MR levels and uPA_SAP competition of [‘?]RAP binding to a2-MR. (A) Time-dependence of 
[‘251]RAP binding during PMA-induced differentiation. a2-MR in PMA-treated U937 cell extracts (150 pug total protein) was resolved on 5% 
SDS-PAGE, blotted on nitrocellulose filters, and incubated with [“‘I]RAP (5 x lo5 cpmlpg) (see section 2). The strips were autoradiographed for 
16 h at -80°C. Lane 1 shows the purified a2-MR (1.5 fig). Lanes 2-5, U937 cells incubated with 150 nM PMA for 0, 20,48, and 72 h, respectively. 
(B) Competition of [‘*‘I]RAP binding to purified a2-MR by uPA_SAP. Purified ct2-MR (1.5 pup) was resolved on 5% SDS-PAGE and electroblotted. 
Individual strips were incubated with different concentration of unlabeled uPA_SAP and then with [?]RAP (10 x 10’ cpm/pg). Autoradiography 
was carried out for 6 h at -80°C. 
dependent manner (Fig. 2B), indicating that a specific interac- 
tion between uPA-SAP and a2-MR takes place. Down-regula- 
tion of a2-MR expression at the cell surface, after 72 h of PMA 
stimulation, is accompanied by a lOOO-fold reduction in cell 
sensitivity to uPA-SAP (Fig. 4A). It must be noted, however, 
that an initial increase in a2-MR levels at 20 h of PMA treat- 
ment did not result in an increase in uPA-SAP sensitivity (Fig. 
4B). This might be explained by the fact that functions subse- 
quent to internalization (i.e. intracellular routing, specific ef- 
fects on protein synthesis or other) are required for uPA-SAP 
cytotoxicity. 
Internalization and degradation of UPA: PAI- complexes 
depend on an initial binding to uPAR which subsequently pre- 
sents the ligand to the a2-MR for internalization [6,7,16]. In- 
deed, undifferentiated U937 cells bind and degrade UPA : PAI- 
complexes [2,3]. uPA:PAI-1 degradation is inhibited by the 
a2-MR ligand RAP, and PMA-induced differentiation of U937 
cells is accompanied by the inhibition of uPA:PAI-1 degrada- 
tion (M. Conese and F. Blasi, unpublished), indicating an es- 
sential role for a2-MR in UPA : PAI- internalization and deg- 
radation. The failure of PMA-treated U937 cells to internalize 
the UPA: PAI- 1 complexes, despite the presence of high levels 
of uPAR, correlates also with the decrease in a2-MR. 
The mechanism underlying PMA-induced down-regulation 
of a2-MR during U937 differentiation remains to be clarified. 
The RNA data, in fact, while confirming the initial increase of 
a2-MR protein and ligand-binding activity after 24 h of treat- 
ment with PMA, do not account for its down-regulation at later 
times (Fig. 5). PMA-induced down-regulation of a2-MR, there- 
fore, does not depend on decreased transcription. Other possi- 
bilities (shedding of receptor molecules from the plasma mem- 
brane or augmented degradation) are now under investigation 
(M. Conese and F. Blasi, in preparation). 
The stimulatory effect of a2-MR mRNA and protein 
by PMA at early times appears to be in agreement with the 
8 $ u937 
Q 9 0 20 48 72 hours 
Fig. 3. Inununo-blotting analysis of IX~-MR expression. RAP-Sepharose 
enriched U937 cell lysates (1 mg proteins) were electrophoresed (5% 
acrylamide SDS-PAGE) and transferred onto a nitrocellulose mem- 
brane. The membrane was probed with anti-d2-MR polyclonal anti- 
body and developed with [“‘Ilprotein A (see section 2). Lane 1, purified 
a2-MR (0.1 mg); lane 2, untreated cells; lane 3, PMA-treatment for 
20 h; lane 4, PMA-treatment for 48 h; lane 5, PMA-treatment for 72 h. 
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regulatory effect of PAI- on cell adhesion. In fact, PMA- and 
cytokine-induced adhesion of myeloid cells is positively regu- 
lated by uPAR occupancy and negatively by PAI-I [32,33]. 
Therefore, further studies are required to investigate the role 
of a2-MR in differentiation-linked phenomena, like cellular 
adherence. The later decrease in a2-MR suggests that macro- 
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Fig. 5. Effect of PMA on a2-MR mRNA levels in U937 cells. Total 
RNA was isolated from U937 cells and used to obtain cDNA from 
which was amplified a sequence of 321 bp (see section 2). Lane I. 
untreated cells; lanes 24, cells treated for 6, 24 and 72 h, respectively; 
lane 5, Hep G2 cells; lane 6, as lane I, RT-PCR run in the absence of 
RNA; lanes 7-12. as lanes 1-6, RT-PCR run in the absence of reverse 
transcriptase. Marker VIII (Boehringer-Mannheim) run alongside (on 
both sides) of the gel: from top to bottom: I I 14.900,692, 501,404,320, 
242, 190 and 147 bp. 
phages might require a lower level of uPA-mediated endocyto- 
sis. This point needs to be further investigated. 
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Fig. 4. uPA_SAP cytotoxicity on PMA-treated U937 cells. (A) Loss of 
uPA_SAP sensitivity upon PMA treatment of U937 cells. Cells cultured 
for 72 h at 37°C in the absence (0) or in the presence CO) of 150 nM 
PMA were washed and incubated at 37°C for 48 h in fresh PMA-free 
medium, in the presence of the indicated concentrations of uPA-SAP. 
The effect of uPA_SAP on cell viability was measured by [‘Hlleucine 
incorporation and is expressed as percent ofcontrol cells. The assay was 
run in quadruplicate. Data represent the means + S.D. (B) Time-course 
of uPA-SAP cytotoxicity during PMA-induced differentiation of U937 
cells. Cells were incubated at 37°C in the presence of 150 nM PMA for 
increasing time lengths. After each time point, PMA-containing me- 
dium was removed, and cells were incubated at 37°C for 48 h in fresh 
PMA-free medium, either in the absence or in the presence of 1 nM 
uPA-SAP. The effect of uPA-SAP on cell viability was measured by 
[‘Hlleucine incorporation and is expressed as percent of control cells. 
Data represent the means t SD. of 8 replicates. 
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